Stocktoria
Laboratorios Farmaceuticos Rovi, S.A. ROVI.MC
Laboratorios Farmaceuticos Rovi, S.A. statistics & valuation
Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value (€28.35); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Laboratorios Farmaceuticos Rovi, S.A. trades at about 20.7× earnings — below its 10-year norm (10-year range 10.4×–26.1×, median 24.5×).
Shaded band = 10-year range (10.4×–26.1×); dot = today's 20.7×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Gross margin | 64.9% | 62.6% | 59.3% | 63.5% |
| Operating margin | 25.0% | 23.5% | 26.6% | 31.3% |
| Net margin | 18.9% | 17.9% | 20.5% | 24.4% |
| FCF margin | 16.0% | 10.0% | 7.0% | 22.8% |
| Return on assets | 14.7% | 16.5% | 21.3% | 22.7% |
| Return on equity | 21.1% | 23.9% | 31.6% | 38.4% |
| Debt / equity | 0.13× | 0.14× | 0.07× | 0.09× |
| Current ratio | 3.13 | 3.13 | 2.55 | 2.12 |
Computed from company filings · ES · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.